MRSN

Mersana Therapeutics Inc

• Dow Jones·01/06 22:08

  *News On Mersana Therapeutics Inc. (MRSN) Now Under DAWN

• TipRanks·01/06 14:49

  Mersana Therapeutics Completes Merger and Delists from Nasdaq

• Reuters·01/06 14:26

  Mersana Therapeutics Shareholders to Receive $25 Per Share in Acquisition by Day One Biopharmaceuticals

• Reuters·01/06 00:50

  NASDAQ TRADE HALT <MRSN.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM

• Reuters·12/11/2025 21:15

  Serina Therapeutics Appoints Dr. Joshua Thomas as Vice President and Head of Chemistry

• Seeking Alpha·12/10/2025 15:26

  AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

• Seeking Alpha·11/15/2025 20:15

  Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more

• TipRanks·11/15/2025 06:01

  Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays

• TipRanks·11/15/2025 03:57

  Mersana Therapeutics to be Acquired by Day One

• Reuters·11/14/2025 20:19

  BUZZ-Nasdaq biotech index hits record high, set to gain nearly 5% this week

• Seeking Alpha·11/14/2025 20:00

  Catalyst Watch: Spotlight on Nvidia's outlook, Walmart's strategy, and Fedspeak

• Dow Jones·11/14/2025 14:25

  Mersana Therapeutics Cut to Neutral From Buy by Guggenheim

• Benzinga·11/14/2025 14:15

  Guggenheim Downgrades Mersana Therapeutics to Neutral

• TipRanks·11/14/2025 13:55

  Morning Movers: Cidara skyrockets following Merck buyout offer

• NASDAQ·11/14/2025 13:10

  Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates